RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Stock Information for RenovoRx Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RenovoRx Inc.

RenovoRx Announces $10 Million at Market Private Placement
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx Establishes RenovoCath® Medical Advisory Board
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
RenovoRx Announces Clinical Data Supporting the TAMP(TM) Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.